SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Chardan Cuts Alnylam Price Target to $375 From $425, Keeps Buy

Chardan lowered its price target on Alnylam Pharmaceuticals to $375 from $425 and maintained a Buy rating.

ALNY

Related stories